Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062803 · ClinicalTrials.gov registry record · Phase 3
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00062803 is a Phase 3 study that has completed, run by Sanofi.
The verdict
NCT00062803, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard treatment includes injections or infusions of an anticoagulant drug, (LMW)heparin, for about a week followed by anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. Assignment to either SR34006 or (LMW)heparin plus warfarin or acenocoumarol will be purely by chance and will be known by both patients and their doctors.
Interventions
- DRUG SR34006
- DRUG (LMW)heparin
- DRUG Warfarin VKA
- DRUG Acenocoumarol VKA
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062803
The ClinicalTrials.gov registry entry for NCT00062803 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which SR34006 is the first listed.
NCT00062803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062803 about?
NCT00062803 is a clinical study titled "SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism". Patients who have a pulmonary embolism (blood clot in the lung) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood-thinning) drug, SR34006, with the standard way of treating a pulmonary embolism. The standard tr...
What is the current status of trial NCT00062803?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-06. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00062803?
The interventions under investigation include: SR34006 (DRUG), (LMW)heparin (DRUG), Warfarin VKA (DRUG), Acenocoumarol VKA (DRUG).
Who is sponsoring clinical trial NCT00062803?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.